FY2025 EPS Estimate for Lantheus Reduced by Analyst

Key Points

• Brookline Capital Management has reduced its FY2025 EPS estimate for Lantheus from $4.78 to $4.76, while the consensus estimate for full-year earnings stands at $6.01 per share.
• Insider Rajiv A. Patel sold 3.36 million shares of Lantheus stock at an average price of $56.15, decreasing their ownership by 49.18%.
• The company holds an average rating of "Moderate Buy" from analysts, with a consensus price target of $74.50.

Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) - Analysts at Brookline Capital Management decreased their FY2025 EPS estimates for Lantheus in a research note issued on Monday, October 13th. Brookline Capital Management analyst K. Dolliver now anticipates that the medical equipment provider will post earnings per share of $4.76 for the year, down from their prior forecast of $4.78. The consensus estimate for Lantheus' current full-year earnings is $6.01 per share. Brookline Capital Management also issued estimates for Lantheus' Q4 2025 earnings at $1.05 EPS and FY2026 earnings at $5.02 EPS.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The company had revenue of $92.51 million for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.

A number of other equities research analysts have also recently weighed in on LNTH. The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the company a "neutral" rating in a report on Wednesday, October 8th. Mizuho cut their price target on Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. B. Riley dropped their target price on Lantheus from $109.00 to $84.00 and set a "buy" rating on the stock in a report on Tuesday, September 16th. William Blair reissued a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Lantheus in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $74.50.

Lantheus Stock Performance

LNTH opened at $55.07 on Wednesday. The business's 50 day moving average is $53.82 and its 200-day moving average is $73.99. The stock has a market cap of $3.74 billion, a PE ratio of 14.65 and a beta of 0.09. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. Lantheus has a twelve month low of $47.25 and a twelve month high of $118.21.

Insider Activity at Lantheus

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,812,000 shares of company stock worth $382,427,380. 2.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC purchased a new position in Lantheus during the 2nd quarter worth approximately $26,000. Osterweis Capital Management Inc. purchased a new position in Lantheus during the 2nd quarter worth approximately $36,000. Signaturefd LLC grew its position in Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 116 shares in the last quarter. Quarry LP grew its position in Lantheus by 2,350.0% during the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock worth $48,000 after purchasing an additional 470 shares in the last quarter. Finally, Hughes Financial Services LLC purchased a new position in Lantheus during the 1st quarter worth approximately $81,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.